Black Friday saleUp to 70% OFF
III

IMMUNOVIA AB

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Seasonals

IMMNOV chart


Full chart

IMMNOV upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪100.98 M‬ SEK
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.304 SEK
Net income (FY)
‪−309.44 M‬ SEK
Revenue (FY)
‪1.57 M‬ SEK
Shares float
‪165.09 M‬
Beta (1Y)
−2.39

Employees


Employees (FY)
11
Change (1Y)
−53 −82.81%
Revenue / Employee (1Y)
‪14.13 K‬ SEK
Net income / Employee (1Y)
‪−2.78 M‬ SEK

About IMMUNOVIA AB


Sector
Health Technology
CEO
Jeff Borcherding
Headquarters
Lund
Website
immunovia.se
Founded
2007
ISIN
SE0006091997
FIGI
BBG00BKSX594
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

IMMNOV news



Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of IMMNOV is 0.619 SEK — it has increased by 2.59% in the past 24 hours. Watch IMMUNOVIA AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange IMMUNOVIA AB stocks are traded under the ticker IMMNOV.
IMMNOV stock has fallen by −3.25% compared to the previous week, the month change is a −13.52% fall, over the last year IMMUNOVIA AB has showed a −74.53% decrease.
IMMNOV reached its all-time high on Sep 29, 2020 with the price of 277.025 SEK, and its all-time low was 0.514 SEK and was reached on Oct 25, 2023. View more price dynamics on IMMNOV chart.
See other stocks reaching their highest and lowest prices.
IMMNOV stock is 7.55% volatile and has beta coefficient of −2.39. Track IMMUNOVIA AB stock price on the chart and check out the list of the most volatile stocks — is IMMUNOVIA AB there?
Today IMMUNOVIA AB has the market capitalization of ‪100.98 M‬, it has decreased by −4.13% over the last week.
Yes, you can track IMMUNOVIA AB financials in yearly and quarterly reports right on TradingView.
IMMUNOVIA AB is going to release the next earnings report on Nov 27, 2024. Keep track of upcoming events with our Earnings Calendar.
IMMNOV net income for the last quarter is ‪−25.60 M‬ SEK, while the quarter before that showed ‪−2.95 M‬ SEK of net income which accounts for −768.87% change. Track more IMMUNOVIA AB financial stats to get the full picture.
No, IMMNOV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 11.00 employees. See our rating of the largest employees — is IMMUNOVIA AB on this list?
Like other stocks, IMMNOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMUNOVIA AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMMUNOVIA AB technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMMUNOVIA AB stock shows the sell signal. See more of IMMUNOVIA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.